Skip to main content
Clinical Trials/NCT05753644
NCT05753644
Recruiting
Not Applicable

The Effect of Preoperative Stellate Ganglion Block on Postoperative Atrial Fibrillation After Video-assisted Thoracoscopic Surgeries: A Randomized Controlled Trial

Peking University People's Hospital1 site in 1 country480 target enrollmentStarted: March 27, 2023Last updated:

Overview

Phase
Not Applicable
Status
Recruiting
Enrollment
480
Locations
1
Primary Endpoint
Primary outcome is the incidence of POAF using dynamic electrocardiogram.

Overview

Brief Summary

The aim of this study is to test if stellate ganglion block can decrease the incidence of atrial fibrillation after video-assisted thoracoscopic surgery and the way it works.

Detailed Description

Postoperative atrial fibrillation (POAF) is a common complication after video-assisted thoracoscopic surgeries. It leads to early postoperative complications, prolonged ICU stay and hospital stay, increased hospital expense and medical system burden. POAF is hard to predict and difficult to treat. The potential mechanism of POAF is not fully understood. Since early 2020, covid-19 overwhelmed globally. Chest X-rays and CT scans prescribed enormously due to screening for covid-19 infection. Lung nodules are frequently discovered and the number of video-assisted thoracoscopic procedures is surged. Prevention and new targets of treatment of POAF need to be investigated urgently. This is a double blinded, randomized controlled trial, investigating the effect of autonomic nervous system modulation on POAF. In current study, patients with one or more POAF risks, who undergo video-assisted thoracoscopic lobectomy will be enrolled and randomized into two groups. Participants in the SGB group receive stellate ganglion blocks (SGB) preoperatively, while those in the control group receive sham blocks. All the patients receive standardized anesthesia and video-assisted thoracoscopic procedures. All of participants will be monitored with portable ECG monitoring for 48 hours to detect any POAF occurrence. Cytokines including IL-2, IL-6 and inflammatory bio-markers including C-reactive protein and white blood cell count are measured before surgery, 24h and 48h after surgery. The primary outcome is the occurrence of POAF and its duration. The sample size is calculated as 191 patients per group. The presumed result will be that SGB will lower the POAF incidence and shorten the duration after video-assisted thoracoscopic surgeries.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Prevention
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • 1.patients undergoing elective thoracoscopic lobectomy;
  • 2.patients with one or more risk factors of POAF. According to literature, risks factors of POAF including male, aged over 65, obesity (BMI\>30kg/m2), cardiac co-morbidity ( hypertension, myocardial infarction, heart failure, arrhythmia, history of valve procedure), diabetes, chronic renal insufficiency (increased creatinine level), obstructive sleep apnea syndrome (diagnosed or STOP-BANG scores ≥3).

Exclusion Criteria

  • patients with permanent atrial fibrillation, left ventricular or right ventricular pacemaker implantation or removal;
  • patients use antiarrhythmic drugs (except beta-blockers);
  • 3.patients use immunosuppressive drugs preoperatively;
  • 4.patients with active infection or sepsis;
  • patients with neurologic disorder;
  • 6.patients with immune deficiency syndrome.

Arms & Interventions

SGB group

Experimental

The subjects will accept ultrasound guided SGB in the right side of the neck in a supine position. The drug is 5 ml of 0.5% ropivacaine.

Intervention: stellate ganglion blocks (Procedure)

SGB group

Experimental

The subjects will accept ultrasound guided SGB in the right side of the neck in a supine position. The drug is 5 ml of 0.5% ropivacaine.

Intervention: Ropivacaine (Drug)

control group

Placebo Comparator

The subjects will accept sham block in the right side of the neck in a supine position. A sham block is performed by subcutaneous infiltration (1 mL1% lidocaine) on the site.

Intervention: stellate ganglion blocks (Procedure)

control group

Placebo Comparator

The subjects will accept sham block in the right side of the neck in a supine position. A sham block is performed by subcutaneous infiltration (1 mL1% lidocaine) on the site.

Intervention: Sham treatment (Drug)

Outcomes

Primary Outcomes

Primary outcome is the incidence of POAF using dynamic electrocardiogram.

Time Frame: within 48 hours post-surgery

Percentage of subjects who experience POAF.

Secondary Outcomes

  • Secondary outcome is the level of inflammatory mediators including IL-2, IL-6, CRP, WBC count.(T0: pre-induction; T1: immediate after surgery; T2: 24 hours after T1; T3: 48 hours after T1. A cycle is 24 hours.)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Juhui

professor

Peking University People's Hospital

Study Sites (1)

Loading locations...

Similar Trials